691
Pill imprint 691 has been identified as Divalproex sodium extended-release 250 mg.
Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; mania; epilepsy; hyperekplexia and belongs to the drug class fatty acid derivative anticonvulsants. There is positive evidence of human fetal risk during pregnancy.
Divalproex sodium 250 mg is not subject to the Controlled Substances Act.
See also related documents.
Divalproex sodium extended-release Images
- Imprint:
-
691
- Strength:
- 250 mg
- Color:
- White
- Size:
- 6.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Fatty acid derivative anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Global Pharmaceuticals
- National Drug Code (NDC):
- 00115-6911
- Inactive Ingredients:
- silicon dioxide
copovidone
calcium phosphate dihydrate dibasic
hydrogenated cottonseed oil
hypromellose
polyethylene glycol
polyvinyl alcohol
magnesium silicate
titanium dioxide
microcrystalline cellulose
stearic acid
xanthan gum
Advertisement
More Divalproex Sodium Extended-Release resources
- Divalproex Delayed-Release Tablets (Wolters Kluwer)
- Divalproex Extended-Release Tablets (Wolters Kluwer)
- Divalproex Sprinkle Capsules (Wolters Kluwer)
- divalproex sodium (Cerner Multum)
- Alti-Valproic (Micromedex) - Includes Dosage Information
- Depakote DR (Micromedex) - Includes Dosage Information
- divalproex sodium (Micromedex) - Includes Dosage Information
- Depakote Pellets (FDA)
- Divalproex Delayed Release (FDA)
- Divalproex Sprinkle (FDA)
Search Again
